H.R. 6342: Compassionate Freedom of Choice Act of 2012

H.R. 6342: Compassionate Freedom of Choice Act of 2012
http://by150w.bay150.mail.live.com/default.aspx?rru=inbox#n=473250270&rru=inbox&fid=1&fav=1&mid=1c4b3ecb-e800-11e1-a667-00237de335f4&fv=1

 112th Congress, 2011–2012. Text as of Aug 02, 2012
(Introduced).


Status & Summary | PDF | Source: GPO

 HR 6342 IH

 112th CONGRESS
 2d Session
 H. R. 6342
To allow the importation, distribution, and sale of investigational drugs and
devices intended for use by terminally ill patients who execute an informed
consent document.
IN THE HOUSE OF REPRESENTATIVES
 August 2, 2012
Mr. PAUL (for himself, Mr. BROUN of Georgia, and Mr. HANNA) introduced the
following bill; which was referred to the Committee on Energy and Commerce
 
A BILL
To allow the importation, distribution, and sale of investigational drugs and devices intended for use by terminally ill patients who execute an informed consent document. 

  Be it enacted by the Senate and House of Representatives of the United
States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ‘Compassionate Freedom of Choice Act of
2012’.

SEC. 2. DRUGS AND DEVICES FOR USE BY TERMINALLY ILL PATIENTS.

The Federal Food, Drug, and Cosmetic Act is amended by inserting after
section 561 (21 U.S.C. 360bbb) the following:

 ‘SEC. 561A. DRUGS AND DEVICES FOR USE BY TERMINALLY ILL PATIENTS.

‘(a) In General- Nothing in this Act or section 351 of the Public Health
Service Act prevents or restricts, and the Food and Drug Administration shall
not implement or enforce any provision of law preventing or restricting, the
importation, distribution, or sale of an investigational drug or device intended
for use by a terminally ill patient in accordance with subsection (b).


‘(b) Patient Requirements- In order for an investigational drug or device to
be intended for use in accordance with this subsection, such drug or device must
be intended for use by a patient who has-- 

‘(1) been diagnosed with a terminal illness by a licensed physician;


‘(2) been informed by a licensed physician that no drug or device that is
lawfully marketed in the United States is likely to cure the illness; and


‘(3) executed a written informed consent document that states--
 

‘(A) the known and potential risks and benefits of such drug or device;
and


‘(B) any indications of the illness for which a drug or device is lawfully
marketed, or for which treatment is otherwise available, in the United
States.



‘(c) Prohibition on Requiring the Disclosure, Collection, and Reporting of
Certain Information by Food and Drug Administration-




‘(1) IN GENERAL- The Commissioner of Food and Drugs may not require the
disclosure, collection, or reporting of--




‘(A) any information related to the delivery, administration, or use of an
investigational drug or device pursuant to this section; or


‘(B) any information related to the clinical outcomes experienced by a
terminally ill patient supplied an investigational drug or device pursuant to
this section.



‘(2) EXCEPTION- Nothing in this subsection prevents the sponsor of a clinical
trial from voluntarily disclosing, collecting, or reporting information to the
Food and Drug Administration.



‘(d) Definition of Investigational Drug or Device- In this section, the term
‘investigational drug or device’ means a drug or device that--




‘(1) has not yet been approved, licensed, or cleared for commercial distribution under section 505, 510(k), or 515 of this Act or section 351 of the Public Health Service Act (42 U.S.C. 262), and cannot otherwise be lawfully marketed in the United States; and


‘(2) is or has been the subject of one or more clinical trials.’.

---